Efficacy and safety of tocilizumab monotherapy in patients with microscopic polyangiitis
Not Applicable
- Conditions
- Microscopic polyangiitis
- Registration Number
- JPRN-UMIN000011242
- Lead Sponsor
- Saitama Medical Center, Saitama Medical University Department of Rheumatology and Clinical Immunology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients who are prohibited to use tocilizumab by the JCR guideline for proper tocilizumab use 2) patients who are thought to be inappropriate for the treatment with tocilizumab by their attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of major clinical signs and symptoms at week 24. (MPO-ANCA or PR3-ANCA, serum CRP and ESR, BVAS2003, VDI)
- Secondary Outcome Measures
Name Time Method Improvement of major clinical signs and symptoms at week 52 Exacerbation of major clinical signs and symptoms at week 104